FFM
MCRB icon

Fairmount Funds Management’s Seres Therapeutics MCRB Stock Holding History

Fairmount Funds Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,651
Closed -$7.27M – 20
2021
Q1 		$7.27M Buy
17,651
+4,800
+37% +$2.21M 3.06% 15
2020
Q4 		$6.3M Buy
+12,851
New +$7.53M 2.25% 16

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Fairmount Funds Management's MCRB Position: Q2 2021 in Review

Fairmount Funds Management sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 17,651 shares — an estimated $7.27M sold.

Fairmount Funds Management first reported a position in MCRB in Q4 2020 and held it in 2 quarters. The position peaked at $7.27M in Q1 2021. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • Fairmount Funds Management reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Fairmount Funds Management sold 17,651 Seres Therapeutics shares in Q2 2021, an estimated $7.27M.
  • Fairmount Funds Management first reported a position in Seres Therapeutics in Q4 2020 and held it in 2 quarters.
  • Fairmount Funds Management's Seres Therapeutics position peaked at $7.27M in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on Fairmount Funds Management's 13F filing for Q2 2021, filed 13 Aug 2021.